Shanghai Sinotau Biotech Co. Ltd. has synthesized tyrosine-protein phosphatase non-receptor type 13 (PTPN13; FAP-1; PTP-1E) inhibitors reported to be useful for the treatment of cancer, inflammation, atherosclerosis, fibrosis and keloid.
Blacksmith Medicines Inc. has disclosed glutaminyl-peptide cyclotransferase-like protein (QPCTL; IsoQC) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, psoriasis, chronic obstructive pulmonary disease, atherosclerosis and Alzheimer’s disease, among others.
Nona Biosciences, a wholly owned subsidiary of HBM Holdings Ltd., has entered into a strategic collaboration with Genequantum Healthcare (Suzhou) Co. Ltd. to advance the early discovery of next-generation bioconjugates.
Alone or combined with chemotherapy, radiation therapy (RT) is the standard therapeutic option for the majority of non-small-cell lung cancer (NSCLC) cases. Unfortunately, the proportion of patients that experience local-regional relapse can reach 50% of cases. Data from previous investigations link KRAS mutations to radioresistance.
Researchers from Tscan Therapeutics Inc. presented preclinical data for TSC-200-A0201, a naturally occurring HPV16 E7-specific T-cell receptor (TCR) T-cell therapy discovered using Tscan’s proprietary Receptorscan platform. It is being developed for the treatment of human papillomavirus 16 (HPV16)-positive solid tumors. The therapeutic TCR in TSC-200-A0201 was introduced into a transposon vector, with the resulting TCR T therapy product being a mixture of cytotoxic and helper T cells, both reprogrammed to recognize HPV16+ HLA-A*02:01+ cells.
MYC amplification and p53 mutations are common in several human cancers. DNA topoisomerase II-β-binding protein (TopBP1) functions at the intersection of Rb, PI3K/Akt and p53 pathways and thus could be a promising cancer therapeutic target.
A Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. patent describes new ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer
Work at Beijing Tide Pharmaceutical Co. Ltd. has led to the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety coupled to an EGFR (HER1; erbB1)-targeting moiety through a linker.
RSS
